MMRGlobal to Grant Royalty-Free Licenses to Universities to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology

LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc . ( OTCQB : MMRF ) ("MMR") today announced that the Company plans on granting royalty-free licenses to universities interested in using the Company's patented antibody technology for research and development into potential therapies in the fight against Ebola.

"In response to the humanitarian Ebola crisis, MMR plans on granting the licenses for research into the development of treatments for Ebola and other infectious diseases," said Robert H. Lorsch, MMRGlobal CEO.

MMRGlobal owns technology that allows for the development and use of therapeutics through production of specific monoclonal antibodies. The technology utilizes proprietary Human Framework Reassembly (HuFR) components in the construction of antibodies, which permits the antibodies to retain their beneficial properties while reducing or eliminating the side-effects seen with other antibodies that are due to the body's reaction to foreign substances.

MMRGlobal's biotech intellectual property portfolio includes patents granted in the United States, Australia, South Korea and Mexico directed to "Antibodies and Methods for Making and Using Them." Additional patents for the Company's antibody technology are also pending in the United States, Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and South Korea.

MMR's antibody technology has been used to produce anti-CD20 monoclonal antibodies having particular utility in fighting cancers. For additional information, contact Investor Relations at info@mmrmail.com .

About MMRGlobal Biotech Patents and Applications

MMRGlobal owns a portfolio of patents and patent applications for the monoclonal antibody technology, including patents and applications covering anti-CD20 antibodies and their production. U.S. Patent No. 8,465,741 protects various antibodies and the methods for making and using them; additional U.S. patent applications are pending. Foreign protection includes patents in Australia, South Korea and Mexico, along with pending applications in Brazil, Canada, China, Hong Kong, India, Europe, and Japan, all originating from international application PCT/US07/78568. The patents provide further detail of the development, structure, manufacture and established assays belonging to MMRGlobal.

In addition to the patents and patent applications, MMRGlobal assets relating to the anti-CD20 antibodies available for transfer include:

  • 29 antibodies generated using the patented methods (including amino acid and gene sequences)
  • Protocols for assays used in the antibody discovery program
  • Anti-CD20 Cellular ELISA and quantitative IgG ELISA
  • CDC (complement-dependent cytotoxicity)
  • ADCC (antibody-dependent cell mediated-cytotoxicity)
  • Apoptosis
  • Cell Cycle
  • Glycerol stocks of the antibodies subcloned into a mammalian expression vector

About MMR Health Information Technology Patents and Applications

In addition to MMRGlobal's biotech patents and intellectual property, the Company, through its wholly owned subsidiary MyMedicalRecords, Inc., is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through the MyMedicalRecords PHR, and MMRPro and MMRProPlus document management and imaging systems for healthcare professionals . MMR currently has 13 issued U.S. health IT patents pertaining to Personal Health Records including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, with over 300 claims, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. In addition to the U.S., MMR currently has patents issued, pending and/or applied for in 11 other countries or regional authorities including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.

About MMRGlobal MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro , is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com . View demos and video tutorials of the Company's products and services at www.mmrtheater.com .

Forward-Looking Statements All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, license, and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT: Bobbie Volman MMRGlobal bvolman@mmrmail.com (310) 476-7002 , Ext. 7015 Michael Selsman Public Communications Co. ms@publiccommunications.biz (310) 922-7033

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 142

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 54

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 156

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 114

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 24

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 121

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Eagle Pharmaceuticals Board Advances Rights Plan for Shareholders

Updated Category News Views 231

Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...

Continue Reading
How Trump's Immigration Policies Could Impact US Growth

Updated Category News Views 338

Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...

Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Ahead

Updated Category News Views 142

Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...

Continue Reading
Join Us for the 2024 AvaSure Symposium Celebrating Virtual Care

Updated Category News Views 90

Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...

Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update

Updated Category News Views 282

Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...

Continue Reading